CorMedix Investor Relations Material

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company develops targeted products for the prevention or treatment of bacterial infections as well as serious and life-threatening diseases that affect a patient's lungs, respiratory tract, gastrointestinal tract, skin, heart valves, throat and mouth. CorMedix Inc.'s marketed product is CERDELIV I.V. injection, an injectable antibacterial indicated for the treatment of patients with complicated urinary tract infections caused by susceptible Gram-negative bacteria. The company markets its products through its sales force which distributes pharmaceuticals primarily to hospitals that are part of integrated healthcare systems.